Huijun Cheng

机构：Zhengzhou University, Henan Cancer Hospital · ORCID：0000-0002-4649-8559

发表论文 9 篇 · 总被引 57 次 · h-index 3

代表论文

• Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy. (2015 · PubMed · 被引 29)
• Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study (2019 · Journal of Gynecologic Oncology · 被引 18)
• 251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase 2 clinical trial (DUBHE-C-206) (2024 · International Journal of Gynecological Cancer · 被引 5)
• miR-26b suppressed cervical cancer cell proliferation and apoptosis by targeting ATF2 through MAPK1/ERK2 pathway (2020 · Minerva Endocrinology · 被引 3)
• Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study. (2025 · Journal of Clinical Oncology · 被引 2)
• 702 Prospective, multicenter study of apatinib in treating gynecological cancer patients: A real-world study from China (2021 · International Journal of Gynecological Cancer)